argenx SE

argenx SE is a commercial-stage biopharmaceutical company that develops therapies for autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx SE is also developing efgartigimod for seronegative gMG, ocular myasthenia gravis (MG), primary ITP, Grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR. Other pipeline candidates include empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. The company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody; ARGX-124, another FcRn pipeline candidate; ARGX-109, which targets IL-6 for inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10. Additional developments include cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. argenx SE has strategic partnerships and license agreements with Zai Lab for efgartigimod; Halozyme Therapeutics for its ENHANZE technology; OncoVerity, Inc. for cusatuzumab; and AbbVie, Inc. for ARGX-115. The company was incorporated in 2008 and is based in Amsterdam, the Netherlands.